Bipolar Disorder (2018) |
1.21 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADD3 LOC147727 |
Bipolar Disorder or Schizophrenia |
1.17 |
7 |
4 |
8.9 |
0.74 |
5.5e-02 |
APOPT1 C11orf80 FANCA FES KLC1 RNF185 SLC25A17 |
Depressed Affect (Nagel 2018) |
1.10 |
5 |
3 |
6.7 |
-0.12 |
8.5e-01 |
KANSL1 LRRC37A2 NEK6 SNAI3-AS1 WNT3 |
Intelligence (Savage-Jansen 2018) |
0.95 |
11 |
5 |
11.1 |
-0.06 |
8.6e-01 |
AP3B2 CEP250 FOXO3 LOC80154 MICU1 PNPO PRKAG1 REST RP11-152F13.3 RPS26 TULP4 |
Neuroticism (Nagel 2018) |
1.16 |
9 |
5 |
11.1 |
0.25 |
4.9e-01 |
ADM KANSL1 LRRC37A2 NCOA6 NEK6 RNF166 SLC25A17 SNAI3-AS1 WNT3 |
Schizophrenia (2018) |
1.07 |
5 |
1 |
2.2 |
0.34 |
5.7e-01 |
APOPT1 FES KLC1 PCNX SLC25A17 |
Worry (Nagel 2018) |
1.16 |
5 |
4 |
8.9 |
0.24 |
6.0e-01 |
ENTPD6 LRRC37A2 NCOA6 SLC25A17 WNT3 |
Alzheimer’s Disease (in mother) |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SLC24A4 |
Alzheimer’s Disease (including proxy) |
1.13 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SLC24A4 |
Crohns Disease (2017) |
1.43 |
12 |
10 |
22.2 |
0.56 |
2.3e-02 |
ADCY3 CUL2 DOCK8 GBAP1 LOC100506472 MSTO2P PARK7 RIT1 RP11-373D23.3 SYNGR1 ZBTB38 ZFP36L2 |
Irritable Bowel Disease (IBD) |
1.43 |
14 |
11 |
24.4 |
0.41 |
6.9e-02 |
ADCY3 CUL2 DOCK8 GBAP1 GIGYF1 LOC100506472 MSTO2P PARK7 RP11-373D23.3 SYNGR1 THBS3 TOM1 ZFP36L2 ZNF831 |
Ulcerative Colitis (UC) |
1.17 |
5 |
2 |
4.4 |
0.21 |
6.5e-01 |
GBAP1 PARK7 SYNGR1 THBS3 TOM1 |
Reaction Time |
1.16 |
6 |
3 |
6.7 |
-0.36 |
4.8e-01 |
ADCY3 ARL17A C11orf80 EXT1 FOXO3 PRKAG1 |
Verbal and Numeric Reasoning (VNR) |
0.97 |
5 |
2 |
4.4 |
-0.46 |
4.4e-01 |
DYNLT1 FADS2 FOXO3 PRKAG1 RPS26 |
Breast Cancer |
2.12 |
17 |
9 |
20.0 |
-0.25 |
3.0e-01 |
ADCY3 ARHGEF5 CCND1 CDKAL1 CDKN2B CORT CTD-2310F14.1 GBAP1 L3MBTL3 LRRC37A2 MIER3 RIT1 RP11-554A11.9 THBS3 TOX3 ZBTB38 ZNF404 |
Ovarian Cancer |
1.23 |
4 |
4 |
8.9 |
1.00 |
1.0e-03 |
CHMP4C KANSL1 LRRC37A2 WNT3 |
Prostate Cancer |
1.52 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RP11-554A11.9 |
Bipolar Disorder (2011) |
1.58 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PRKAG1 |
Body Mass Index (BMI) (2010) |
1.25 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ADCY3 RP11-6N17.10 |
Coronary Artery Disease (CAD) |
1.43 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
B9D2 CDKN2B SPG7 |
Crohns Disease (2012) |
1.30 |
6 |
3 |
6.7 |
0.87 |
1.1e-02 |
ADCY3 CUL2 GBAP1 MSTO2P RIT1 ZFP36L2 |
Fasting Glucose |
1.08 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
AC074117.10 |
HbA1C |
1.59 |
2 |
1 |
2.2 |
-0.99 |
2.1e-05 |
B3GNTL1 FN3KRP |
HDL Cholesterol |
1.14 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACP2 KIF5A POLA2 |
LDL Cholesterol |
1.16 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
DHX38 EFCAB13 FADS2 |
Neuroticism (2016) |
1.03 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADM SLC25A17 |
Primary Biliary Cirrhosis |
1.37 |
2 |
1 |
2.2 |
-0.99 |
1.3e-04 |
LOC100506472 SYNGR1 |
Rheumatoid Arthritis |
1.22 |
3 |
1 |
2.2 |
-0.65 |
3.5e-01 |
FADS2 SYNGR1 TRAF1 |
Schizophrenia (2014) |
1.04 |
6 |
2 |
4.4 |
0.16 |
7.3e-01 |
APOPT1 FES GIGYF1 GNB2 KLC1 SLC25A17 |
Triglycerides |
1.27 |
5 |
3 |
6.7 |
0.65 |
2.4e-01 |
AC074117.10 FADS2 KIF5A NRBP1 RP11-373D23.3 |
Type 2 Diabetes (T2D) (2012) |
1.20 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
JAZF1 |
Ulcerative Colitis |
1.14 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CUL2 PARK7 |
Blood Eosinophil Count |
0.79 |
35 |
21 |
46.7 |
0.29 |
6.9e-02 |
ADCY3 ADD3 APOPT1 B3GNTL1 C14orf153 COMMD7 CUL2 DNMT3B DUSP6 ERMP1 EXOC2 FADS2 FAM136A GIGYF1 GNB2 JAZF1 KANSL1 KAT5 KLC1 LRRC37A2 NMRAL1 NUCB2 POC1B PPM1A PSMB7 RANBP6 RERE REST RP11-981P6.1 RPS26 SLC25A17 SLC38A2 WNT3 ZFP36L2 ZNF831 |
Blood Platelet Count |
0.90 |
61 |
43 |
95.6 |
0.10 |
4.1e-01 |
AAMDC AC067945.4 AC074117.10 ADD3 ALKBH5 ARL17A BANP C20orf203 CBFA2T2 CDKAL1 CDKN2B COMT COX4I2 DOCK8 EDNRB EFCAB13 FADS2 FAM136A FLJ43663 GALNS GBAP1 GPR98 HMBS IFITM3 INTS4 KANSL1 KAT5 KIF5A LOC147727 LRRC37A2 MITF NDNL2 NMRAL1 NRBP1 NUCB2 NUDC PCNX PLXNA1 PNPO POC1B POLA2 PSMB7 RALY RERE REST RP11-554A11.9 RPL13 SLC38A2 SMCR7 SNRNP27 SYNGR1 TCF12 THBS3 TOM1 TRAF1 TRIM47 TULP4 UFSP1 WNT3 ZFP36L2 ZFPM1 |
Blood Red Count |
1.29 |
65 |
49 |
108.9 |
-0.10 |
3.9e-01 |
ADM AKAP9 ALKBH5 ANXA3 AP3B2 APRT ARL17A ASPSCR1 BCL2L1 BMP2K C11orf80 C12orf29 C14orf153 C20orf203 C4orf22 CBFA2T2 CBWD1 COX4I2 DEF8 DHX38 DOCK8 EFCAB13 ENTPD6 FADS2 FAM136A FANCA GALNS GBAP1 GIGYF1 GNB2 IFITM3 KANSL1 KIF5A KITLG L3MBTL3 LOC80154 LRRC37A2 MITF MKRN2 MYADML2 NCOA6 P4HB PNPO POLA2 RNF166 RP11-152F13.3 RP5-1085F17.3 RPL13 RPS26 RSL24D1P6 SCRN2 SMCR7 SNAI3-AS1 SPG7 SUPT3H TBC1D4 TBCD THBS3 TMEM163 TRIP6 UCHL3 UFSP1 VPS9D1 WNT3 ZBTB38 |
Blood White Count |
0.91 |
41 |
28 |
62.2 |
-0.06 |
6.8e-01 |
AC074117.10 ADCY3 C12orf29 C14orf153 COMT CORT EDNRB FADS2 FES FLJ43663 GOLGA5 IFITM3 IL16 KANSL1 KITLG KLC1 L3MBTL3 MSL1 NEK6 NMRAL1 NRBP1 NUCB2 PNPO POC1B PSMB7 RALY REST RNF185 RP11-373D23.3 RP11-554A11.9 RP11-6N17.10 RP11-6N17.6 SCRN2 SLC39A12 SNAI3-AS1 TPCN2 TRAF1 TULP4 VPS9D1 ZFP36L1 ZNF76 |
Heel T-Score |
1.42 |
64 |
51 |
113.3 |
0.19 |
9.3e-02 |
ACP2 ACSF3 APOPT1 ASPSCR1 ATL1 AXL B9D2 BNC2 BOLA1 C11orf58 C14orf153 CBWD1 CLIC5 DENND1A DOCK8 DUS1L EIF3E FBLN5 GAB2 GBAP1 IGHMBP2 INTS4 JAZF1 KANSL1 KAT5 KLC1 L3MBTL3 LNX1 LRRC37A2 LRRC45 MASP2 MRAS MRPL21 NCOA6 NEK6 NUDC PARD3 PKDCC PRKAG1 PSMB7 RALY RERE REST RP11-169K16.9 RP11-529H20.5 RP11-529H20.6 RP11-554A11.9 RP11-6N17.6 RP4-614O4.12 SLC25A17 STRA13 THBS3 TPCN2 TRIP11 TSPAN10 TULP4 TWIST1 UFSP1 USP35 WNT3 ZBTB38 ZFP36L2 ZNF404 ZNF76 |
BMI |
1.10 |
36 |
25 |
55.6 |
-0.09 |
5.9e-01 |
ACP2 ADCY3 ALKBH3 APOPT1 C14orf153 C4orf22 COMT DHX36 DUS1L EDNRB ENTPD6 FOXO3 GAB2 GBAP1 HMBS HMGB1 IGHMBP2 JAZF1 KLC1 L3MBTL3 LDHA MANBAL MASP2 MED23 MRPL21 NAALAD2 PKHD1 POC1B PSMB7 RALY RNF219 RP11-6N17.10 RP11-981P6.1 RPS26 STRA13 ZCCHC24 |
Height |
1.71 |
127 |
105 |
233.3 |
-0.20 |
1.0e-02 |
AAMDC AC074117.10 ACP2 ACSF3 ADCY3 ADM AKAP9 ALKBH5 APOPT1 APRT ARL17A ASPSCR1 ATXN3 AXIN2 B9D2 BEND3P3 BOLA1 C14orf153 C2orf82 C9orf156 CBFA2T2 CDH15 CEP250 CHMP4B CNTLN COMMD7 CTC-435M10.6 CTD-2310F14.1 CTD-2555A7.3 DBNDD1 DHFR DHX38 DNMT3B DUS1L EDEM2 EDNRB EFCAB13 EIF3E EXOC2 EZR FAM136A FANCA FN3KRP FOXO3 GAB2 GNB2 GNS GRB2 GTF2H1 HEBP1 IGHMBP2 IL16 IL20RB INTS4 JAZF1 KANSL1 KLC1 L3MBTL3 LHX2 LOC147727 LRRC37A2 LRRC45 MAPRE1 MASP2 MICU1 MIR3614 MKRN2 MRAS MRGPRF MROH8 MRPL10 MRPL45P2 MSL1 MVD MYADML2 NAALAD2 NCOA6 NDRG3 NRBP1 NUCB2 NUDC PAX3 PDGFB PKDCC PLUNC PNPO POLA2 PPM1A PROCR RALGPS1 RALY REST RNF166 RP11-268J15.5 RP11-373D23.3 RP11-529H20.5 RP11-529H20.6 RP11-554A11.9 RP11-6N17.6 RP11-815J21.2 RP1-184J9.2 RP4-614O4.12 RPL13 RPL41P1 SAMHD1 SEC22A SLC38A2 SNAI3 SNAI3-AS1 SPG7 STRA13 SYNGR1 TBCD TOM1 TPCN2 TRIP11 TULP4 URAHP USP35 VGLL4 WNT3 ZBTB38 ZFP36L2 ZFPM1 ZNF341 ZNF76 ZNF831 |
Waist Hip Ratio (WHR) |
1.32 |
32 |
26 |
57.8 |
-0.08 |
6.4e-01 |
ADM ALKBH5 ARL17A ASPSCR1 CDKAL1 EDEM2 EML3 GRB2 HMBS JAZF1 KANSL1 KAT5 L3MBTL3 LOC147727 LRP5 LRRC37A2 LRRC45 MKRN2 MRAS MYADML2 MYEOV NMRAL1 PCNX RNF185 RP11-554A11.9 STX17 TET2 TOM1 TPCN2 WNT3 ZCCHC24 ZFP36L2 |
Systolic Blood Pressure |
1.34 |
38 |
25 |
55.6 |
0.31 |
5.1e-02 |
AC074117.10 ACP2 ADCY3 ADM ARL17A ATP2B1 C4orf22 CBWD1 COMMD7 CUL2 DHX36 DOCK8 EFCAB13 FES FOXO3 IGHMBP2 KAT5 MRAS MRGPRF NUCB2 PCNX PNPO POC1B POLA2 RP11-373D23.3 RP11-6N17.6 RP11-761I4.4 RP11-981P6.1 SCRN2 SMCR7 SPG7 TOX3 TRIM47 TRIP6 UFSP1 WDPCP WNT3 ZNF831 |
Smoking Status |
1.02 |
4 |
0 |
0.0 |
0.66 |
3.4e-01 |
APOPT1 HMGB1 RPS26 SORBS3 |
Allergy or Eczema |
1.28 |
11 |
7 |
15.6 |
0.47 |
1.0e-01 |
JAZF1 NEK6 PSMB7 RIT1 RP11-373D23.3 RP1-184J9.2 RPS26 SLC25A17 SPOP TRAF1 ZBTB38 |
Cardiovascular Disease |
1.32 |
20 |
14 |
31.1 |
0.19 |
3.8e-01 |
AC074117.10 ACP2 APOPT1 ATP2B1 BCL2L1 C14orf153 C4orf22 DHX38 EFCAB13 FES MRAS NUCB2 PCNX POC1B POLA2 RP11-981P6.1 SNF8 SNX16 VPS9D1 ZNF831 |
Hypothyroidism (self reported) |
1.41 |
10 |
5 |
11.1 |
0.14 |
6.3e-01 |
C9orf156 FADS2 GIGYF1 GNB2 NIPAL3 PSMB7 RPS26 SDF4 SYNGR1 TRIM47 |
Respiratory disease |
1.09 |
7 |
6 |
13.3 |
-0.08 |
8.6e-01 |
ERMP1 FADS2 JAZF1 KIF5A RP11-207C16.4 RPS26 ZNF76 |
Type 2 Diabetes (T2D) (2018) |
1.37 |
8 |
7 |
15.6 |
-0.45 |
2.3e-01 |
AC074117.10 CBFA2T2 CDKAL1 CHMP4B JAZF1 MRAS ZCCHC24 ZFP36L2 |
Lung FEV1/FVC ratio |
1.10 |
34 |
20 |
44.4 |
0.01 |
9.7e-01 |
ADCY3 ADD3 ADM ANXA3 ATP2B1 BOLA1 BTBD1 DHX36 EIF3E EXOC2 EZR FOXO3 GAB2 HMBS IFITM3 KCTD21 MRPL10 MSL1 NARS2 NMRAL1 PROCR RALY REST RP11-268J15.5 RP11-6N17.6 RPS26 RSL24D1P6 SPOP STRA13 TEKT5 USP35 ZBTB38 ZFP36L2 ZNF76 |
Lung FVC |
1.42 |
42 |
31 |
68.9 |
0.17 |
2.4e-01 |
AC067945.4 AP3B2 ASPSCR1 ATXN3 BTBD1 C11orf80 CEP250 CORT COX4I2 EDEM2 EML3 FAM136A FOXO3 GBAP1 GOLGA5 GRB2 IGHMBP2 JAZF1 KANSL1 LRRC37A2 MICU1 MRAS MRPL21 MYADML2 NCOA6 NDRG3 NMRAL1 PLXNA1 PROCR RAC3 RALY RP11-529H20.5 RP11-529H20.6 RP11-6N17.10 SNAI3-AS1 THBS3 TRIP11 TULP4 TWIST1 WNT3 ZBTB38 ZCCHC24 |
Neuroticism |
1.18 |
11 |
5 |
11.1 |
0.29 |
3.5e-01 |
ADM GAB2 KANSL1 KCTD21 LRRC37A2 MAP1LC3B NCOA6 SLC25A17 SNAI3-AS1 USP35 WNT3 |
Chronotype (morning person) |
0.87 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C11orf80 LOC147727 |
Tanning |
10.85 |
82 |
69 |
153.3 |
-0.76 |
9.4e-28 |
AC074117.10 ACSF3 ADAMTS12 ADCY3 AMACR AP3B2 AP3M2 APRT BCL2L1 BNC2 C11orf58 C9orf150 C9orf72 CBFA2T2 CDH15 CEP250 CHMP4B CNTLN COMMD7 CTD-2555A7.3 CTSC CYBA DBNDD1 DCT DEF8 DHX38 DNMT3B EDEM2 ENTPD6 EXOC2 FANCA GAB2 GALNS GBAP1 GPR98 GRB2 HERC2 IGHMBP2 IRF4 JAZF1 KCTD21 LOC80154 LURAP1L MANBAL MAPRE1 MMP24-AS1 MPDZ MROH8 MVD NAALAD2 NCOA6 NDRG3 NPLOC4 OCA2 PLUNC PROCR RALY RNF166 RP11-152F13.3 RP11-373D23.3 RP11-554A11.9 RP11-6N17.6 RP4-614O4.12 RP5-1085F17.3 RP5-1142A6.5 RPL13 RXFP3 SAMHD1 SNAI3 SNAI3-AS1 SPG7 SYNGR1 TMTC3 TPCN2 TRIP11 TSPAN10 TYRP1 URAHP USP35 VPS9D1 ZFPM1 ZNF341 |
Hand grip strength (left) |
1.10 |
13 |
8 |
17.8 |
0.19 |
5.4e-01 |
ADCY3 CEP250 CORT EMB KANSL1 L3MBTL3 LRRC37A2 PROCR RP4-614O4.12 SLC22A23 SLC38A2 WNT3 ZBTB38 |
Number of treatments/medications taken |
1.18 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACSF3 COMMD7 ZNF831 |
Sensitivity / hurt feelings |
1.07 |
4 |
3 |
6.7 |
-0.71 |
2.9e-01 |
FES KANSL1 LRRC37A2 WNT3 |
Relative age of first facial hair |
1.80 |
19 |
11 |
24.4 |
0.50 |
3.1e-02 |
ALX4 C4orf22 CNOT6L DBNDD1 DEF8 FANCA FLJ43663 FOXO3 HERC2 KANSL1 LRRC37A2 MASP2 MIR3614 MRPL10 SLC39A12 TSPAN10 TWIST1 WNT3 ZBTB38 |
Systolic blood pressure, automated reading |
1.16 |
11 |
10 |
22.2 |
0.50 |
1.2e-01 |
ACP2 ADM ATP2B1 C4orf22 FES POC1B RP11-6N17.6 RP11-981P6.1 TOX3 WNT3 ZNF831 |
Angina |
1.33 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CDKN2B FES |
Medication: Metformin |
1.21 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
JAZF1 MRAS ZCCHC24 |
Diabetes (father) |
1.28 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKAL1 ZFP36L2 |
Diabetes (mother) |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CDKAL1 |
Pack years adult smoking proportion |
0.96 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GNA12 KLC1 |
Impedance of leg (right) |
1.22 |
32 |
16 |
35.6 |
0.09 |
5.7e-01 |
ADCY3 ADM APOPT1 BOLA1 C11orf80 CEP250 EDNRB FES GBAP1 IGHMBP2 JAZF1 KLC1 L3MBTL3 LRP5 MANBAL MAPRE1 MRGPRF MRPL21 MSTO2P MYEOV NCOA6 NDUFS4 PRKAG1 RALY RIT1 RNF166 RNF185 SLC38A2 SNAI3-AS1 SUPT3H TPCN2 ZFP36L2 |
Leg fat-free mass (left) |
1.45 |
42 |
24 |
53.3 |
-0.07 |
6.4e-01 |
AC074117.10 C2orf82 CBFA2T2 CEP250 CTC-435M10.6 CTD-2555A7.3 EDEM2 EDNRB ENTPD6 FOXO3 GBAP1 IGHMBP2 JAZF1 L3MBTL3 LOC147727 LRP5 MASP2 MRGPRF MROH8 MRPL21 MSL1 NCOA6 NDRG3 NDUFS4 PROCR RALY REST RNF219 RP11-268J15.5 RP1-184J9.2 RP4-614O4.12 RPL13 SLC38A2 SNAI3-AS1 SPG7 SYNGR1 TPCN2 TRIP11 TULP4 TYRP1 ZBTB38 ZNF76 |
Trunk fat percentage |
1.11 |
21 |
13 |
28.9 |
-0.35 |
1.1e-01 |
ADCY3 ADM ARL17A BOLA1 CNOT6L DBNDD1 DEF8 ENTPD6 FANCA FOXO3 HMGB1 MRPL45P2 NDUFS4 PKHD1 POC1B RALGPS1 RP11-6N17.10 RP11-981P6.1 TMEM163 WNT3 ZBTB38 |
Hand grip strength (right) |
1.09 |
12 |
7 |
15.6 |
0.16 |
6.2e-01 |
ADCY3 CEP250 CORT L3MBTL3 LRRC37A2 MAPRE1 PROCR RP4-614O4.12 TMEM163 TULP4 WNT3 ZBTB38 |
Current tobacco smoking |
1.05 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOPT1 LDHA |
Maternal smoking around birth |
1.10 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOPT1 KLC1 |
Fed-up feelings |
1.10 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
KANSL1 LRRC37A2 WNT3 |
Relative age voice broke |
1.24 |
5 |
3 |
6.7 |
-0.35 |
5.6e-01 |
ALX4 FOXO3 KANSL1 LRRC37A2 WNT3 |
Age when periods started (menarche) |
0.94 |
6 |
5 |
11.1 |
-0.40 |
4.3e-01 |
ADCY3 AKAP12 FOXO3 GAB2 NUCB2 USP35 |
Heel bone mineral density (BMD) T-score, automated (left) |
1.22 |
6 |
2 |
4.4 |
0.65 |
1.2e-01 |
ACP2 C14orf153 FADS2 KAT5 REST TPCN2 |
Qualifications: CSEs or equivalent |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KANSL1 |
High blood pressure |
1.28 |
10 |
7 |
15.6 |
0.23 |
5.3e-01 |
ACP2 ATP2B1 BCL2L1 C14orf153 C4orf22 FES MRAS NUCB2 SNF8 ZNF831 |
Hayfever, allergic rhinitis or eczema |
1.26 |
9 |
5 |
11.1 |
0.46 |
2.1e-01 |
JAZF1 NEK6 PSMB7 RP11-373D23.3 RP1-184J9.2 RPS26 TRAF1 TUFT1 ZBTB38 |
Stomach or abdominal pain in last month |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GIGYF1 |
Medication: Atenolol |
1.04 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Medication: Levothyroxine sodium |
1.28 |
4 |
1 |
2.2 |
0.94 |
5.6e-02 |
C9orf156 GIGYF1 RPS26 SDF4 |
Sitting height |
1.63 |
58 |
40 |
88.9 |
-0.15 |
2.3e-01 |
AC074117.10 ACP2 ADCY3 ADM ALKBH5 APRT ASPSCR1 B9D2 C14orf153 C2orf82 CBFA2T2 CEP250 COX4I2 CTC-435M10.6 CTD-2555A7.3 DNMT3B EDEM2 EDNRB FAM136A FOXO3 IGHMBP2 JAZF1 KANSL1 L3MBTL3 LOC147727 LRP5 LRRC37A2 LRRC45 MASP2 MRGPRF MROH8 MSL1 MYADML2 NCOA6 NDRG3 NDUFS4 NUDC PNPO PROCR RAC3 RALY REST RP11-529H20.5 RP11-529H20.6 RP1-184J9.2 RP4-614O4.12 RPL13 SEC22A SLC38A2 SNAI3-AS1 STRA13 TOM1 TRIP11 TULP4 VGLL4 WNT3 ZBTB38 ZNF831 |
High blood pressure (mother) |
1.26 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES NUCB2 ZNF831 |
Body mass index (BMI) |
1.01 |
18 |
10 |
22.2 |
-0.01 |
9.8e-01 |
ADCY3 ALKBH3 APOPT1 C14orf153 DENND1A ENTPD6 FOXO3 GBAP1 HMGB1 IGHMBP2 JAZF1 KLC1 MED23 PKHD1 POC1B RNF219 RP11-6N17.10 RPS26 |
Impedance of leg (left) |
1.21 |
31 |
19 |
42.2 |
0.07 |
6.8e-01 |
ADCY3 ADM ALDH3B1 BOLA1 CEP250 EDNRB FES GBAP1 IGHMBP2 JAZF1 KANSL1 KLC1 L3MBTL3 LRP5 MANBAL MASP2 MRGPRF MRPL21 MSTO2P NCOA6 NDUFS4 PRKAG1 RALY RIT1 RNF185 SLC38A2 SNAI3-AS1 SUPT3H TPCN2 WNT3 ZFP36L2 |
Leg predicted mass (left) |
1.44 |
43 |
23 |
51.1 |
-0.07 |
6.5e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 CTC-435M10.6 CTD-2555A7.3 EDEM2 EDNRB ENTPD6 FOXO3 GBAP1 IGHMBP2 JAZF1 L3MBTL3 LOC147727 LRP5 MASP2 MRGPRF MROH8 MRPL21 MSL1 NCOA6 NDRG3 NDUFS4 PROCR RALY REST RNF219 RP11-268J15.5 RP1-184J9.2 RP4-614O4.12 RPL13 SLC38A2 SNAI3-AS1 SPG7 SYNGR1 TPCN2 TRIP11 TULP4 TYRP1 ZBTB38 ZNF76 |
Trunk fat mass |
1.15 |
22 |
13 |
28.9 |
-0.36 |
9.2e-02 |
ADCY3 ARL17A BOLA1 CEP250 DBNDD1 DEF8 DENND1A ENTPD6 FANCA FOXO3 GBAP1 HMGB1 L3MBTL3 MRPL45P2 NDRG3 PKHD1 POC1B RNF219 RP11-6N17.10 RP11-981P6.1 RPL13 ZBTB38 |
Waist circumference |
1.04 |
16 |
9 |
20.0 |
-0.23 |
3.7e-01 |
ADCY3 ARL17A DENND1A ENTPD6 FOXO3 HMBS HMGB1 KLC1 NDRG3 PKHD1 POC1B RP11-6N17.10 RP11-981P6.1 RPL13 ZBTB38 ZCCHC24 |
Number of incorrect matches in round |
1.01 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
EXT1 TULP4 |
Nervous feelings |
1.13 |
5 |
0 |
0.0 |
0.82 |
2.5e-02 |
LRRC37A2 NCOA6 RAC3 SLC25A17 WNT3 |
Frequency of tenseness / restlessness in last 2 weeks |
0.99 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
KANSL1 LRRC37A2 WNT3 |
Hearing difficulty/problems with background noise |
1.24 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C14orf153 KLC1 |
Hair/balding pattern: Pattern 2 |
2.17 |
8 |
7 |
15.6 |
-0.26 |
5.3e-01 |
AXIN2 C4orf22 COMMD7 LRRC37A2 PAX3 RPL41P1 TWIST1 WNT3 |
Had menopause |
1.16 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AC074117.10 FANCA NRBP1 |
Forced vital capacity (FVC) |
1.38 |
27 |
19 |
42.2 |
0.23 |
2.2e-01 |
ACP2 ADCY3 ARL17A ASPSCR1 CBFA2T2 COMMD7 DNMT3B EDNRB FAM136A KANSL1 L3MBTL3 LOC147727 LRRC37A2 LRRC45 MRPL21 MYADML2 RAC3 REST RP11-268J15.5 RP11-6N17.10 RP11-6N17.6 SNAI3-AS1 TULP4 WNT3 ZBTB38 ZCCHC24 ZNF76 |
Heel bone mineral density (BMD) T-score, automated (right) |
1.29 |
9 |
5 |
11.1 |
0.66 |
3.8e-02 |
ACP2 C14orf153 FADS2 KAT5 REST RP11-169K16.9 RP11-554A11.9 TPCN2 ZNF76 |
Ever unenthusiastic/disinterested for a whole week |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LRRC37A2 |
Qualifications: None of the above |
1.03 |
4 |
1 |
2.2 |
0.90 |
3.8e-02 |
AP3B2 FOXO3 RANBP6 RPS26 |
Financial difficulties in last 2 years |
1.14 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOPT1 |
Mouth/teeth dental problems |
1.18 |
3 |
1 |
2.2 |
-1.00 |
3.7e-04 |
GBAP1 KLC1 THBS3 |
Heart attack |
1.19 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B FES |
Allergy |
1.27 |
10 |
7 |
15.6 |
-0.53 |
9.5e-02 |
ERMP1 FADS2 JAZF1 KIF5A MSL1 NEK6 PSMB7 RPS26 TRAF1 ZBTB38 |
Diabetes (self-reported) |
1.29 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
AC074117.10 JAZF1 ZCCHC24 |
Medication: Simvastatin |
1.23 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
DHX38 FES ZNF831 |
Fluid intelligence score |
0.92 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
FOXO3 PRKAG1 RPS26 |
Illnesses of siblings |
1.06 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Neuroticism score |
1.10 |
7 |
6 |
13.3 |
0.17 |
7.1e-01 |
ADM KANSL1 LRRC37A2 NCOA6 SLC25A17 SNAI3-AS1 WNT3 |
Weight |
1.30 |
34 |
23 |
51.1 |
-0.25 |
1.2e-01 |
ADCY3 ALKBH3 CBFA2T2 CEP250 CTD-2555A7.3 DENND1A EDEM2 EDNRB ENTPD6 FOXO3 GBAP1 IGHMBP2 L3MBTL3 LOC147727 MASP2 MROH8 MRPL21 MVD NCOA6 NDRG3 PDGFB PKHD1 POC1B RALY RNF219 RP11-373D23.3 RP11-6N17.10 RP11-981P6.1 RP4-614O4.12 RPL13 SLC38A2 SYNGR1 TYRP1 ZBTB38 |
Impedance of arm (right) |
1.30 |
34 |
20 |
44.4 |
-0.10 |
5.3e-01 |
ADM ARL17A ATL1 BOLA1 CEP250 CORT DBNDD1 EDEM2 FOXO3 GAB2 HMGN2 INTS4 JAZF1 KCTD21 L3MBTL3 LRRC37A2 MANBAL MASP2 MRPL10 MRPL21 NCOA6 NDUFS4 NEK6 PRKAG1 PSMB7 RALGPS1 RALY RNF185 RP11-554A11.9 RPS26 SLC38A2 UCHL3 USP35 WNT3 |
Arm fat percentage (right) |
1.06 |
16 |
9 |
20.0 |
-0.23 |
3.5e-01 |
ACP2 ADCY3 ADM APOPT1 ARL17A C14orf153 ENTPD6 GBAP1 HMGB1 KLC1 PKHD1 POC1B RALGPS1 RNF219 RP11-6N17.10 RP11-981P6.1 |
Trunk fat-free mass |
1.56 |
44 |
31 |
68.9 |
-0.05 |
7.4e-01 |
AC074117.10 ADM ALDH3B1 C14orf153 C2orf82 CBFA2T2 CEP250 CTC-435M10.6 EDEM2 EDNRB ENTPD6 FOXO3 IGHMBP2 IRF4 JAZF1 L3MBTL3 LOC147727 MASP2 MRGPRF MROH8 MRPL21 MSL1 NCOA6 NDRG3 PROCR RALGPS1 RALY REST RP11-268J15.5 RP11-373D23.3 RP11-529H20.6 RP1-184J9.2 RP4-614O4.12 RPL13 RPS26 SLC38A2 SPG7 SYNGR1 TPCN2 TRIP11 TULP4 TYRP1 ZBTB38 ZNF76 |
Hip circumference |
1.09 |
21 |
13 |
28.9 |
-0.26 |
2.6e-01 |
ADCY3 CEP250 ENTPD6 FOXO3 L3MBTL3 LOC147727 MASP2 NDRG3 PDGFB PKHD1 POC1B RALY RNF219 RP11-6N17.10 RP1-184J9.2 RP11-981P6.1 SLC38A2 SYNGR1 TOM1 TPCN2 ZBTB38 |
Father's age at death |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Worrier / anxious feelings |
1.03 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
SLC25A17 WNT3 |
Frequency of tiredness / lethargy in last 2 weeks |
1.02 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRRG4 |
Hair/balding pattern: Pattern 3 |
1.93 |
9 |
7 |
15.6 |
0.69 |
4.2e-02 |
B9D2 C4orf22 KANSL1 LRRC37A2 MIR3614 PAX3 RPL41P1 TWIST1 WNT3 |
Number of live births |
1.04 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
DBNDD1 FADS2 |
Forced expiratory volume in 1-second (FEV1) |
1.45 |
23 |
18 |
40.0 |
0.21 |
2.9e-01 |
ADCY3 ARL17A ASPSCR1 CBFA2T2 CCND1 FAM136A IGHMBP2 KANSL1 L3MBTL3 LOC147727 LRRC37A2 LRRC45 MRPL21 MYADML2 RAC3 REST RSL24D1P6 SNAI3-AS1 TULP4 WNT3 ZBTB38 ZCCHC24 ZNF76 |
Pulse rate |
1.36 |
4 |
4 |
8.9 |
-0.51 |
3.0e-01 |
GIGYF1 GNB2 TRIP6 ZBTB38 |
Mouth/teeth dental problems: Dentures |
1.24 |
3 |
2 |
4.4 |
0.99 |
1.2e-03 |
ADCY3 GBAP1 THBS3 |
Asthma |
1.08 |
6 |
4 |
8.9 |
-0.13 |
8.1e-01 |
ERMP1 FADS2 JAZF1 KIF5A RPS26 ZNF76 |
Medication: Cholesterol lowering |
1.18 |
5 |
2 |
4.4 |
-0.22 |
7.2e-01 |
AC074117.10 CDKN2B DHX38 FES LOC147727 |
Prospective memory result |
1.22 |
3 |
2 |
4.4 |
-1.00 |
1.6e-03 |
AP3B2 LOC80154 RP11-152F13.3 |
Illnesses of mother |
1.06 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.39 |
25 |
16 |
35.6 |
0.26 |
1.8e-01 |
ACP2 ADCY3 ARL17A ASPSCR1 CBFA2T2 CCND1 EML3 FAM136A IGHMBP2 KANSL1 L3MBTL3 LOC147727 LRRC37A2 LRRC45 MRPL21 MYADML2 RAC3 REST RSL24D1P6 SNAI3-AS1 TULP4 WNT3 ZBTB38 ZCCHC24 ZNF76 |
Impedance of arm (left) |
1.28 |
33 |
18 |
40.0 |
-0.19 |
2.7e-01 |
ADM ATL1 BOLA1 C11orf58 CEP250 CORT DBNDD1 DEF8 EDEM2 FOXO3 GAB2 JAZF1 KANSL1 KCTD21 L3MBTL3 LRRC37A2 MRPL10 MRPL34 NCOA6 NDUFS4 NEK6 PSMB7 RALGPS1 RALY RNF185 RP11-554A11.9 RPS26 SLC38A2 SPG7 TRIP11 UCHL3 USP35 WNT3 |
Arm fat mass (right) |
1.08 |
19 |
11 |
24.4 |
-0.23 |
3.1e-01 |
ADCY3 ALKBH3 APOPT1 ENTPD6 FOXO3 GBAP1 HMGB1 IGHMBP2 KLC1 L3MBTL3 NDRG3 PKHD1 POC1B RALY RNF219 RP11-6N17.10 RP11-981P6.1 RPL13 ZBTB38 |
Trunk predicted mass |
1.57 |
46 |
31 |
68.9 |
-0.06 |
6.8e-01 |
AC074117.10 ADM ALDH3B1 C14orf153 C2orf82 CBFA2T2 CEP250 COMT CTC-435M10.6 EDEM2 EDNRB ENTPD6 FAM136A FOXO3 IGHMBP2 IRF4 JAZF1 L3MBTL3 LOC147727 MASP2 MRGPRF MROH8 MRPL21 MSL1 NCOA6 NDRG3 PROCR RALGPS1 RALY REST RP11-268J15.5 RP11-373D23.3 RP11-529H20.6 RP1-184J9.2 RP4-614O4.12 RPL13 RPS26 SLC38A2 SPG7 SYNGR1 TPCN2 TRIP11 TULP4 TYRP1 ZBTB38 ZNF76 |
Standing height |
1.60 |
83 |
64 |
142.2 |
-0.16 |
1.1e-01 |
AC074117.10 ACP2 ACSF3 ADCY3 ADM ALKBH5 APRT ARL17A ASPSCR1 ATXN3 B9D2 BOLA1 C14orf153 C2orf82 C9orf156 CBFA2T2 CEP250 COMMD7 CTC-435M10.6 CTD-2310F14.1 CTD-2555A7.3 DBNDD1 DHX38 DNMT3B DUS1L EDEM2 EDNRB EFCAB13 FAM136A FANCA FN3KRP FOXO3 GNS GRB2 HEBP1 IL20RB JAZF1 L3MBTL3 LOC147727 LRRC45 MASP2 MKRN2 MROH8 MRPL10 MRPL45P2 MSL1 MVD MYADML2 NAALAD2 NCOA6 NDRG3 NUDC PDGFB PLUNC PNPO PROCR RALGPS1 RALY REST RP11-268J15.5 RP11-373D23.3 RP11-529H20.5 RP11-529H20.6 RP11-6N17.6 RP1-184J9.2 RP4-614O4.12 RPL13 SEC22A SLC38A2 SNAI3-AS1 SORBS3 SPG7 STRA13 SYNGR1 TOM1 TPCN2 TRIP11 TULP4 URAHP WNT3 ZBTB38 ZNF76 ZNF831 |
Tense / 'highly strung' |
0.98 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NCOA6 SLC25A17 |
Seen doctor (GP) for nerves, anxiety, tension or depression |
1.03 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
DENND1A |
Hair/balding pattern: Pattern 4 |
2.74 |
31 |
24 |
53.3 |
0.08 |
6.8e-01 |
ATL1 B9D2 C4orf22 CBWD1 CDKAL1 CORT CTC-435M10.6 DBNDD1 EIF3E EXOC2 FAM136A HMGB1 KANSL1 LNX1 LRRC37A2 MAPRE1 MASP2 MIR3614 MYEOV PLXNA1 RP4-614O4.12 RPL41P1 S100A16 STPG1 SUPT3H TCF12 TWIST1 TWIST2 WNT3 ZBTB38 ZFP36L2 |
Birth weight of first child |
1.18 |
5 |
2 |
4.4 |
0.32 |
6.0e-01 |
ASPSCR1 FES RAC3 SEC22A ZBTB38 |
Peak expiratory flow (PEF) |
1.40 |
14 |
5 |
11.1 |
0.61 |
1.6e-02 |
ASPSCR1 BTBD1 KANSL1 LOC147727 LRRC37A2 LRRC45 MYADML2 REST SDF4 STRA13 TULP4 WNT3 ZFP36L2 ZNF76 |
Blood clot in the leg (DVT) |
1.16 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PROCR |
Medication: Paracetamol |
1.16 |
4 |
4 |
8.9 |
-1.00 |
3.3e-03 |
DENND1A KANSL1 LRRC37A2 WNT3 |
Headache pain in last month |
1.09 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
KANSL1 LRRC37A2 WNT3 |
Medication for cholesterol, blood pressure or diabetes |
1.22 |
4 |
3 |
6.7 |
-0.12 |
8.8e-01 |
ATP2B1 CHMP4B FES ZNF831 |
Glaucoma (self-reported) |
1.07 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B |
Gout (self-reported) |
1.12 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
AC074117.10 KIF5A |
Hypothyroidism/myxoedema (self-reported) |
1.38 |
6 |
3 |
6.7 |
0.24 |
4.8e-01 |
C9orf156 GIGYF1 GNB2 RPS26 SDF4 SYNGR1 |
Medication: Amlodipine |
0.93 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Birth weight |
1.15 |
7 |
3 |
6.7 |
-0.18 |
6.4e-01 |
C11orf21 EDNRB FES L3MBTL3 RIT1 RPS26 TULP4 |
High blood pressure (siblings) |
1.20 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
FES |
Forced vital capacity (FVC), Best measure |
1.36 |
25 |
20 |
44.4 |
0.24 |
2.2e-01 |
ACP2 ADCY3 ARL17A ASPSCR1 CBFA2T2 EDNRB FAM136A KANSL1 L3MBTL3 LOC147727 LRRC37A2 LRRC45 MRAS MRPL21 MYADML2 RAC3 REST RP11-268J15.5 RP11-6N17.6 SNAI3-AS1 TULP4 WNT3 ZBTB38 ZCCHC24 ZNF76 |
Body fat percentage |
1.05 |
18 |
8 |
17.8 |
-0.28 |
2.5e-01 |
ACP2 ADCY3 ADM C14orf153 CNOT6L DBNDD1 DEF8 ENTPD6 FANCA FOXO3 HMGB1 PKHD1 POC1B RALGPS1 RNF219 RP11-6N17.10 RP11-981P6.1 ZBTB38 |
Leg fat percentage (right) |
1.02 |
14 |
6 |
13.3 |
-0.32 |
2.6e-01 |
ADCY3 ADM C14orf153 CNOT6L DUS1L ENTPD6 HMGB1 POC1B PROCR RERE RP11-6N17.10 RP11-981P6.1 TSPAN10 ZCCHC24 |
Arm fat-free mass (right) |
1.46 |
36 |
28 |
62.2 |
-0.14 |
3.9e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 EDEM2 EDNRB ENTPD6 FOXO3 IGHMBP2 IRF4 JAZF1 L3MBTL3 LOC147727 MASP2 MRGPRF MROH8 MRPL21 NCOA6 NDRG3 PROCR PSMB7 RALGPS1 RALY REST RP11-268J15.5 RP11-373D23.3 RP1-184J9.2 RP4-614O4.12 RPL13 SLC38A2 SPG7 SYNGR1 TYRP1 ZBTB38 ZNF76 |
Comparative body size at age 10 |
1.39 |
4 |
2 |
4.4 |
0.22 |
7.8e-01 |
ADCY3 ARL17A KANSL1 PRKAG1 |
Worry too long after embarrassment |
1.15 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DBNDD1 NCOA6 |
Wheeze or whistling in the chest in last year |
1.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SNAI3-AS1 |
Qualifications: College or University degree |
0.91 |
9 |
6 |
13.3 |
-0.15 |
6.9e-01 |
C11orf80 EDEM2 EXT1 FOXO3 KANSL1 LRRC37A2 RANBP6 RPS26 WNT3 |
Medication for pain relief, constipation, heartburn |
1.23 |
4 |
1 |
2.2 |
-0.82 |
1.8e-01 |
DENND1A LRRC37A2 NRBP1 WNT3 |
Medication: Blood pressure |
1.12 |
6 |
4 |
8.9 |
0.18 |
7.4e-01 |
ACP2 ATP2B1 BCL2L1 C4orf22 FES ZNF831 |
Angina (self-reported) |
1.37 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CDKN2B FES |
Medication: Allopurinol |
1.06 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
AC074117.10 KIF5A |
Mean time to correctly identify matches |
1.14 |
5 |
3 |
6.7 |
0.51 |
3.0e-01 |
ARL17A C11orf80 FOXO3 GTF2H1 PRKAG1 |
Heart disease (mother) |
1.14 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B |
Whole body fat mass |
1.08 |
15 |
11 |
24.4 |
-0.24 |
3.7e-01 |
ADCY3 DBNDD1 DENND1A ENTPD6 FOXO3 HMGB1 L3MBTL3 NDRG3 PKHD1 POC1B RNF219 RP11-6N17.10 RP11-981P6.1 RPL13 ZBTB38 |
Leg fat mass (right) |
1.03 |
15 |
9 |
20.0 |
-0.22 |
4.0e-01 |
ADCY3 DENND1A ENTPD6 FOXO3 HMGB1 L3MBTL3 PKHD1 POC1B RALY RERE RNF219 RP11-6N17.10 RP11-981P6.1 RPL13 ZBTB38 |
Arm predicted mass (right) |
1.45 |
37 |
30 |
66.7 |
-0.13 |
4.0e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 EDEM2 EDNRB ENTPD6 FOXO3 IGHMBP2 IRF4 JAZF1 L3MBTL3 LOC147727 MASP2 MRGPRF MROH8 MRPL21 NCOA6 NDRG3 PROCR PSMB7 RALGPS1 RALY REST RP11-268J15.5 RP11-373D23.3 RP1-184J9.2 RP4-614O4.12 RPL13 RPS26 SLC38A2 SPG7 SYNGR1 TYRP1 ZBTB38 ZNF76 |
Pulse rate, automated reading |
1.58 |
14 |
8 |
17.8 |
-0.31 |
2.2e-01 |
AC074117.10 BTBD1 CNOT6L FADS2 GAB2 GIGYF1 GNB2 HMGN2 IL16 RP11-529H20.5 RPS26 TRIP6 USP35 ZBTB38 |
Alcohol intake frequency. |
0.82 |
4 |
3 |
6.7 |
-0.39 |
6.1e-01 |
AC074117.10 KANSL1 LRRC37A2 WNT3 |
Comparative height size at age 10 |
1.47 |
45 |
35 |
77.8 |
0.14 |
3.5e-01 |
AC074117.10 ACP2 ADCY3 ASPSCR1 B9D2 BOLA1 C14orf153 C2orf82 C9orf156 CBFA2T2 CEP250 COMMD7 CTC-435M10.6 DNMT3B FAM136A FOXO3 GRB2 JAZF1 L3MBTL3 LOC147727 LRRC45 MAPRE1 MASP2 MKRN2 MROH8 MSL1 MYADML2 NCOA6 NDRG3 NUCB2 PROCR REST RP11-268J15.5 RP11-529H20.5 RP11-529H20.6 RP11-6N17.6 RP4-614O4.12 SEC22A SPG7 TRIP11 TULP4 WNT3 ZBTB38 ZFP36L2 ZNF76 |
Overall health rating |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KLC1 |
Medication: Aspirin |
1.15 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B FES |
Knee pain experienced in last month |
1.09 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CEP250 EDEM2 LOC147727 |
Hypertension (Self-reported) |
1.25 |
11 |
5 |
11.1 |
0.26 |
4.5e-01 |
ACP2 ATP2B1 BCL2L1 C14orf153 C4orf22 FES MRAS NUCB2 SNF8 VPS9D1 ZNF831 |
Illnesses of father: Heart disease |
1.32 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CDKN2B FES |
Smoking status: Previous |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GBAP1 |
Forced expiratory volume in 1-second (FEV1), predicted |
1.36 |
9 |
4 |
8.9 |
-0.24 |
5.4e-01 |
CBFA2T2 CEP250 JAZF1 L3MBTL3 NCOA6 PROCR TRIP11 ZBTB38 ZNF76 |
Whole body fat-free mass |
1.52 |
45 |
31 |
68.9 |
-0.06 |
6.7e-01 |
AC074117.10 ADM ALDH3B1 C2orf82 CBFA2T2 CEP250 CTC-435M10.6 CTD-2555A7.3 EDEM2 EDNRB EFCAB13 ENTPD6 FOXO3 GBAP1 IGHMBP2 IRF4 JAZF1 L3MBTL3 LOC147727 LRP5 MASP2 MRGPRF MROH8 MRPL21 MSL1 NCOA6 NDRG3 PROCR RALY REST RNF219 RP11-268J15.5 RP11-373D23.3 RP1-184J9.2 RP4-614O4.12 RPL13 SLC38A2 SPG7 SYNGR1 TPCN2 TRIP11 TULP4 TYRP1 ZBTB38 ZNF76 |
Leg fat-free mass (right) |
1.46 |
39 |
24 |
53.3 |
-0.14 |
3.4e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 CTD-2555A7.3 EDEM2 EDNRB ENTPD6 FOXO3 GBAP1 IGHMBP2 IRF4 JAZF1 L3MBTL3 LOC147727 LRP5 MASP2 MRGPRF MROH8 MRPL21 NCOA6 NDRG3 NDUFS4 PROCR RALY REST RNF219 RP11-268J15.5 RP4-614O4.12 RPL13 SLC38A2 SNAI3-AS1 SPG7 SYNGR1 TPCN2 TULP4 ZBTB38 ZNF76 |
Arm fat percentage (left) |
1.06 |
16 |
9 |
20.0 |
-0.25 |
3.1e-01 |
ACP2 ADCY3 ADM ALKBH3 APOPT1 C14orf153 ENTPD6 GBAP1 HMGB1 KLC1 PKHD1 POC1B RALGPS1 RNF219 RP11-6N17.10 RP11-981P6.1 |
Average weekly red wine intake |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C11orf80 |
Handedness (chirality/laterality): Left-handed |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
WNT3 |
Mood swings |
1.20 |
6 |
4 |
8.9 |
-0.26 |
6.1e-01 |
KANSL1 LRRC37A2 MAP1LC3B SLC25A17 SNAI3-AS1 WNT3 |
Long-standing illness, disability or infirmity |
1.13 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
EMB MRAS |
Diabetes diagnosed by doctor |
1.31 |
5 |
3 |
6.7 |
-0.38 |
5.3e-01 |
AC074117.10 CHMP4B JAZF1 ZCCHC24 ZFP36L2 |
Mouth/teeth dental problems: Mouth ulcers |
0.96 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
KANSL1 LRRC37A2 WNT3 |
Medication for cholesterol |
1.11 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C4orf22 ZNF831 |
Breast cancer (self-reported) |
1.24 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CTD-2310F14.1 TOX3 |
Asthma (self-reported) |
1.09 |
6 |
4 |
8.9 |
-0.13 |
8.1e-01 |
ERMP1 FADS2 JAZF1 KIF5A RPS26 ZNF76 |
Osteoarthritis (self-reported) |
0.97 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LOC147727 |
Medication: Aspirin |
1.14 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B FES |
Illnesses of father: None of the above (group 1) |
1.15 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
CDKN2B FES |
Smoking status: Current |
1.09 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GTF2H1 LDHA |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.13 |
5 |
3 |
6.7 |
0.63 |
2.6e-01 |
ASPSCR1 EML3 KANSL1 LRRC37A2 WNT3 |
Whole body water mass |
1.52 |
43 |
30 |
66.7 |
-0.07 |
6.2e-01 |
AC074117.10 ADM ALDH3B1 C2orf82 CBFA2T2 CEP250 CTC-435M10.6 CTD-2555A7.3 EDEM2 EDNRB ENTPD6 FOXO3 GBAP1 IGHMBP2 IRF4 L3MBTL3 LOC147727 LRP5 MASP2 MRGPRF MROH8 MRPL21 MSL1 NCOA6 NDRG3 PROCR RALY REST RNF219 RP11-268J15.5 RP11-373D23.3 RP1-184J9.2 RP4-614O4.12 RPL13 SLC38A2 SPG7 SYNGR1 TPCN2 TRIP11 TULP4 TYRP1 ZBTB38 ZNF76 |
Leg predicted mass (right) |
1.46 |
39 |
24 |
53.3 |
-0.14 |
3.4e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 CTD-2555A7.3 EDEM2 EDNRB ENTPD6 FOXO3 GBAP1 IGHMBP2 IRF4 JAZF1 L3MBTL3 LOC147727 LRP5 MASP2 MRGPRF MROH8 MRPL21 NCOA6 NDRG3 NDUFS4 PROCR RALY REST RNF219 RP11-268J15.5 RP4-614O4.12 RPL13 SLC38A2 SNAI3-AS1 SPG7 SYNGR1 TPCN2 TULP4 ZBTB38 ZNF76 |
Arm fat mass (left) |
1.08 |
18 |
12 |
26.7 |
-0.25 |
2.8e-01 |
ADCY3 ALKBH3 APOPT1 ENTPD6 FOXO3 GBAP1 HMGB1 KLC1 L3MBTL3 NDRG3 PKHD1 POC1B RALY RNF219 RP11-6N17.10 RP11-981P6.1 RPL13 ZBTB38 |
Number of self-reported non-cancer illnesses |
1.33 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ZNF831 |
Average weekly champagne plus white wine intake |
1.09 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
KANSL1 LRRC37A2 WNT3 |
Miserableness |
1.07 |
4 |
1 |
2.2 |
-0.01 |
9.9e-01 |
KANSL1 LRRC37A2 SNAI3-AS1 WNT3 |
Eye problems/disorders: Glaucoma |
1.06 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B |
Medication: Blood pressure |
1.25 |
9 |
3 |
6.7 |
0.40 |
2.8e-01 |
ACP2 C4orf22 FES KAT5 MRAS MYEOV RP5-1142A6.2 VPS9D1 ZNF831 |
Supplements: Fish oil (including cod liver oil) |
1.06 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C11orf80 |
High cholesterol (Self-reported) |
1.32 |
6 |
2 |
4.4 |
0.79 |
6.3e-02 |
AC074117.10 DHX38 EFCAB13 FAM136A LOC147727 RASA3 |
Medication: Bendroflumethiazide |
1.07 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATP2B1 FES ZNF831 |
Medication: Paracetamol |
1.15 |
3 |
3 |
6.7 |
0.00 |
1.0e+00 |
KANSL1 LRRC37A2 WNT3 |
Medication: Lisinopril |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZNF831 |
Medication: Atorvastatin |
1.28 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
AC074117.10 CDKN2B |
Illnesses of father: High blood pressure |
1.21 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C4orf22 FES |
Ever smoked |
0.96 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
REST |
Basal metabolic rate |
1.48 |
42 |
31 |
68.9 |
-0.10 |
5.0e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 CTC-435M10.6 CTD-2555A7.3 EDEM2 EDNRB ENTPD6 FOXO3 GBAP1 IGHMBP2 IRF4 L3MBTL3 LOC147727 MASP2 MRGPRF MROH8 MRPL21 MSL1 MVD NCOA6 NDRG3 PROCR RALY REST RNF219 RP11-268J15.5 RP11-373D23.3 RP1-184J9.2 RP4-614O4.12 RPL13 SLC38A2 SPG7 SYNGR1 TPCN2 TRIP11 TULP4 TYRP1 ZBTB38 ZNF76 |
Leg fat percentage (left) |
1.03 |
14 |
5 |
11.1 |
-0.25 |
3.6e-01 |
ADCY3 ADM C14orf153 DUS1L ENTPD6 FOXO3 HMGB1 POC1B PROCR RERE RP11-6N17.10 RP11-981P6.1 SORBS3 ZCCHC24 |
Arm fat-free mass (left) |
1.47 |
36 |
30 |
66.7 |
-0.10 |
5.1e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 EDEM2 EDNRB ENTPD6 FOXO3 IGHMBP2 IRF4 L3MBTL3 LOC147727 MASP2 MRGPRF MROH8 MRPL21 NCOA6 NDRG3 PROCR PSMB7 RALY REST RP11-268J15.5 RP11-373D23.3 RP1-184J9.2 RP4-614O4.12 RPL13 RPS26 SLC38A2 SPG7 SYNGR1 TRIP11 TYRP1 ZBTB38 ZNF76 |
Irritability |
1.21 |
6 |
4 |
8.9 |
0.43 |
2.9e-01 |
KANSL1 LRRC37A2 NCOA6 RNF219 SLC25A17 WNT3 |
Risk taking |
0.98 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOPT1 KLC1 |
Ever had prostate specific antigen (PSA) test |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZBTB38 |
Diastolic blood pressure, automated reading |
1.09 |
12 |
7 |
15.6 |
-0.07 |
8.0e-01 |
ACP2 ADM ATP2B1 C4orf22 FES GIGYF1 GNB2 INTS4 KAT5 KCTD21-AS1 MIER3 ZNF831 |
Vascular/heart problems diagnosed by doctor |
1.30 |
11 |
7 |
15.6 |
-0.16 |
6.4e-01 |
ACP2 ATP2B1 BCL2L1 C14orf153 C4orf22 FES MRAS NUCB2 SNF8 SNX16 ZNF831 |
Cholesterol lowering medication |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
AC074117.10 |
Basal cell carcinoma (self-reported) |
1.64 |
3 |
2 |
4.4 |
0.81 |
9.8e-02 |
CDKN2B DBNDD1 NCOA6 |
Heart attack/myocardial infarction (self-reported) |
1.17 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CDKN2B FES |
Deep venous thrombosis (DVT) (self-reported) |
1.17 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
NCOA6 PROCR |
Heart disease (siblings) |
0.96 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FES |
Pack years of smoking |
1.00 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GNA12 KLC1 |
Impedance of whole body |
1.21 |
37 |
23 |
51.1 |
-0.13 |
4.0e-01 |
ADCY3 ADM ALDH3B1 BOLA1 C11orf80 CEP250 CORT DBNDD1 EDEM2 EDNRB FOXO3 GAB2 HMGN2 IGHMBP2 JAZF1 KANSL1 KCTD21 L3MBTL3 LRRC37A2 MANBAL MASP2 MRPL21 NCOA6 NDUFS4 NEK6 PRKAG1 PSMB7 RALY RNF185 RP11-554A11.9 RPS26 SLC38A2 SPG7 SUPT3H UCHL3 USP35 WNT3 |
Leg fat mass (left) |
1.03 |
14 |
9 |
20.0 |
-0.18 |
5.3e-01 |
ADCY3 DENND1A ENTPD6 FOXO3 HMGB1 L3MBTL3 PKHD1 POC1B RALY RERE RNF219 RP11-6N17.10 RP11-981P6.1 ZBTB38 |
Arm predicted mass (left) |
1.47 |
36 |
26 |
57.8 |
-0.14 |
3.9e-01 |
AC074117.10 ADM C2orf82 CBFA2T2 CEP250 EDEM2 EDNRB ENTPD6 FOXO3 IGHMBP2 IRF4 L3MBTL3 LOC147727 MASP2 MRGPRF MROH8 MRPL21 NCOA6 NDRG3 PROCR PSMB7 RALGPS1 RALY REST RP11-268J15.5 RP11-373D23.3 RP1-184J9.2 RP4-614O4.12 RPL13 RPS26 SLC38A2 SPG7 SYNGR1 TYRP1 ZBTB38 ZNF76 |